Join

Compare · MRK vs ROIV

MRK vs ROIV

Side-by-side comparison of Merck & Company Inc. (MRK) and Roivant Sciences Ltd. (ROIV): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MRK and ROIV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • MRK is the larger of the two at $298.33B, about 14.5x ROIV ($20.56B).
  • Over the past year, MRK is up 53.4% and ROIV is up 157.2% - ROIV leads by 103.7 points.
  • MRK has been more active in the news (26 items in the past 4 weeks vs 6 for ROIV).
  • MRK has more recent analyst coverage (25 ratings vs 18 for ROIV).
PerformanceMRK+53.44%ROIV+157.18%
2025-06-09+0.00%2026-06-08
MetricMRKROIV
Company
Merck & Company Inc.
Roivant Sciences Ltd.
Price
$121.58+0.58%
$28.43-0.49%
Market cap
$298.33B
$20.56B
1M return
+8.34%
+0.64%
1Y return
+53.44%
+157.18%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
News (4w)
26
6
Recent ratings
25
18
MRK

Merck & Company Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

ROIV

Roivant Sciences Ltd.

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Latest MRK

Latest ROIV